
    
      Given the poor prognosis and the currently existed therapeutic strategies, The investigators
      will perform a prospective, randomized, phase II to III, intergroup trial to compare
      carboplatin plus paclitaxel (TC) with the DAC-primed TC (DTC) regimen in previously untreated
      patients with stage II to IV ovarian cancer.
    
  